$CELG Headlines What to do while the instituti
Post# of 94214
Posted On: 02/09/2015 10:36:50 AM
$CELG Headlines
What to do while the institutions sit on the sideline 3:26 p.m. Feb. 5, 2015 - The Trading Deck
Celgene revenue rises on cancer-drug sales 8:04 a.m. Jan. 29, 2015 - MarketWatch.com
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
No Deceleration Here: 14 Stocks With Accelerating Profits 5:29 p.m. Feb. 6, 2015 - Investors Business Daily
4 (More) Biotech Stocks to Buy 8:06 a.m. Feb. 6, 2015 - InvestorPlace.com
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog 4:20 p.m. Feb. 5, 2015 - Zacks.com
Predictable Fast Growing Healthcare Dividend Growth And Growth Stocks For Your Retirement Portfolios: Part 5 11:51 a.m. Feb. 5, 2015 - Seeking Alpha
The Idiocy Of Gilead's Undervaluation 11:17 a.m. Feb. 5, 2015 - Seeking Alpha
Violent Market Swings - Cramer's Mad Money (2/4/15) 7:20 a.m. Feb. 5, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead 8:26 p.m. Feb. 4, 2015 - TheStreet.com
Oil, Earnings, Strong U.S. Dollar Keeping Stocks in 'No Man's Land' 2:26 p.m. Feb. 4, 2015 - TheStreet.com
Celleration Acquisition Just the Start of Alliqua's M&A Strategy 1:18 p.m. Feb. 4, 2015 - GuruFocus.com
3 Stocks Dragging In The Health Care Sector 12:13 p.m. Feb. 4, 2015 - TheStreet.com
Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog 11:47 a.m. Feb. 4, 2015 - Zacks.com
Jim Cramer: Don't Bail on Biotech or Chipotle Mexican Grill 10:58 a.m. Feb. 4, 2015 - TheStreet.com
Today's Market: Stocks On The Rise, Blowout Earnings And Dividend Increases 10:44 a.m. Feb. 4, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Fiat, It's Sensation 6:00 a.m. Feb. 4, 2015 - TheStreet.com
Chicken Is A Commodity - Cramer's Lightning Round (2/3/15) 5:40 a.m. Feb. 4, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: What a Difference a Month Makes 8:19 p.m. Feb. 3, 2015 - TheStreet.com
Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog 6:15 p.m. Feb. 3, 2015 - Zacks.com
Top Performing Funds Favor Leisure, Medical, REITs 5:22 p.m. Feb. 3, 2015 - Investors Business Daily
Eli Lilly/Boehringer Type II Diabetes Drug Gains FDA Nod - Analyst Blog 4:55 p.m. Feb. 3, 2015 - Zacks.com
Portfolio Managers Love These 5 Biotech Stocks 8:37 a.m. Feb. 3, 2015 - 247WallSt.com
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Feb. 5, 2015 - PR Newswire - PRF
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics 9:00 a.m. Feb. 4, 2015 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
What to do while the institutions sit on the sideline 3:26 p.m. Feb. 5, 2015 - The Trading Deck
Celgene revenue rises on cancer-drug sales 8:04 a.m. Jan. 29, 2015 - MarketWatch.com
Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
No Deceleration Here: 14 Stocks With Accelerating Profits 5:29 p.m. Feb. 6, 2015 - Investors Business Daily
4 (More) Biotech Stocks to Buy 8:06 a.m. Feb. 6, 2015 - InvestorPlace.com
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog 4:20 p.m. Feb. 5, 2015 - Zacks.com
Predictable Fast Growing Healthcare Dividend Growth And Growth Stocks For Your Retirement Portfolios: Part 5 11:51 a.m. Feb. 5, 2015 - Seeking Alpha
The Idiocy Of Gilead's Undervaluation 11:17 a.m. Feb. 5, 2015 - Seeking Alpha
Violent Market Swings - Cramer's Mad Money (2/4/15) 7:20 a.m. Feb. 5, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead 8:26 p.m. Feb. 4, 2015 - TheStreet.com
Oil, Earnings, Strong U.S. Dollar Keeping Stocks in 'No Man's Land' 2:26 p.m. Feb. 4, 2015 - TheStreet.com
Celleration Acquisition Just the Start of Alliqua's M&A Strategy 1:18 p.m. Feb. 4, 2015 - GuruFocus.com
3 Stocks Dragging In The Health Care Sector 12:13 p.m. Feb. 4, 2015 - TheStreet.com
Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog 11:47 a.m. Feb. 4, 2015 - Zacks.com
Jim Cramer: Don't Bail on Biotech or Chipotle Mexican Grill 10:58 a.m. Feb. 4, 2015 - TheStreet.com
Today's Market: Stocks On The Rise, Blowout Earnings And Dividend Increases 10:44 a.m. Feb. 4, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Fiat, It's Sensation 6:00 a.m. Feb. 4, 2015 - TheStreet.com
Chicken Is A Commodity - Cramer's Lightning Round (2/3/15) 5:40 a.m. Feb. 4, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: What a Difference a Month Makes 8:19 p.m. Feb. 3, 2015 - TheStreet.com
Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog 6:15 p.m. Feb. 3, 2015 - Zacks.com
Top Performing Funds Favor Leisure, Medical, REITs 5:22 p.m. Feb. 3, 2015 - Investors Business Daily
Eli Lilly/Boehringer Type II Diabetes Drug Gains FDA Nod - Analyst Blog 4:55 p.m. Feb. 3, 2015 - Zacks.com
Portfolio Managers Love These 5 Biotech Stocks 8:37 a.m. Feb. 3, 2015 - 247WallSt.com
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Feb. 5, 2015 - PR Newswire - PRF
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics 9:00 a.m. Feb. 4, 2015 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼